Protocol of Pakistan randomized and observational trial to evaluate coronavirus treatment among newly diagnosed patients with COVID-19: Azithromycin, Oseltamivir, and Hydroxychloquine
Metadatos
Mostrar el registro completo del ítemEditorial
Professional Medical Publications
Materia
SARS-CoV-2 Hydroxychloroquine Azithromycin Oseltamivir Multi-center Adaptive Randomization Health Off-label
Fecha
2022-05-18Referencia bibliográfica
Azhar S... [et al.]. Protocol of Pakistan randomized and observational trial to evaluate coronavirus treatment among newly diagnosed patients with COVID-19: Azithromycin, Oseltamivir, and Hydroxychloquine. Pak J Med Sci. 2022;38(5):1401-1408. doi: [https://doi.org/10.12669/pjms.38.5.5512]
Patrocinador
Spanish GovernmentResumen
Background & Objective: This study aimed to assess the clinical effectiveness of Hydroxychloroquine
Sulfate (200 mg orally 8 hourlies thrice a day for 5 days), oseltamivir (75 mg orally twice a day for 5
days), and Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5)
alone and in combination (in seven groups).
Methods & Analysis: An adaptive design is deployed, set within a comprehensive cohort study, to permit
flexibility in fast-changing clinical and public health scenario. Primary outcomes include turning the test
negative for coronavirus nucliec acid and in bringing about clinical improvement on day 7 of follow-up
on a seven-point ordinal scale. The randomized study will recruit participants of either gender above
18 years of age who will test positive for SARS-CoV-2 on Quantitative Reverse Transcription Polymerase
Chain Reaction (PCR). Pregnant or lactating females, and those with severe respiratory distress, or
with serious comorbidities will be excluded. Randomization will be done maintaining concealment of
allocation sequence using a computer-generated random number list. The sample size will be subjected
to periodic reviews by National Data Safety and Monitoring Board.
Ethics and Dissemination: The trial is approved by the National Bioethics Committee (No.4-87/NBC-
471-COVID-19-05/20/) and institutional Ethical Review Committee. This clinical trial conducted under
Good Clinical Practice is expected to inform patients clinical guidelines for the use of these drugs in
newly diagnosed with SARS-CoV-2.